Laurus Labs informs about standalone and consolidated financial results

24 Oct 2024 Evaluate
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that the Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024 at their meeting held today i.e., October 24, 2024, which are enclosed along with Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE x and National Stock Exchange of India viz. www.bseindia.com and www.nseinda.com respectively. The Board Meeting commenced at 02.00 PM and concluded at 02.50 PM.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

580.25 6.80 (1.19%)
17-Mar-2025 13:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1701.95
Dr. Reddys Lab 1146.95
Cipla 1492.25
Lupin 2001.10
Zydus Lifesciences 893.35
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...